



# Market Announcement

24 July 2020

---

## MGC Pharmaceuticals Ltd (ASX: MXC) – Suspension from Official Quotation

### Description

The securities of MGC Pharmaceuticals Ltd ('MXC') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MXC, pending the release of an announcement in relation to safety and toxicity pre-clinical study results on ArtemiC.

### Issued by

**Madeleine Green**

Senior Adviser, Listings Compliance (Perth)

24 July 2020

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltsp Perth@asx.com.au](mailto:tradinghaltsp Perth@asx.com.au)

Dear Sir/Madam

**MGC Pharmaceuticals Ltd – Voluntary Suspension Request**

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests a voluntary suspension over the Company’s securities from the commencement of trade on Friday 24 July 2020.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the request:

1. The voluntary suspension request by the Company pending an announcement in relation to safety and toxicity pre-clinical study results on ArtemiC.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Monday 27 July 2020, when it anticipates it will be in a position to make a detailed announcement to the market in respect of the abovementioned release.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

*[signed electronically without signature]*

Rachel Kerr  
Company Secretary